A New VISTA in Intracellular Checkpoint Signaling in Triple-Negative Breast Cancer.

Immune checkpoint inhibitors have transformed treatment paradigms in multiple tumor types including triple-negative breast cancer. However, clinical benefit in metastatic disease is restricted to patients with PD-L1-positive tumors, and primary and acquired resistance remains common among treated patients. These challenges have prompted interest in novel immune checkpoints such as V-domain immunoglobulin suppressor of T-cell activation (VISTA), a B7 family protein with complex immunoregulatory functions. Although VISTA is expressed in multiple tumor types and increasingly explored as a therapeutic target, its exact signaling mechanisms remain unclear. In this issue of Cancer Research, Zhao and colleagues demonstrated that VISTA suppresses tumor growth in a subset of VISTA-expressing triple-negative breast cancers via a cell-intrinsic, immune-independent mechanism. They discovered a conserved four-amino acid motif (NPGF) in VISTA's intracellular domain that mediates its antiproliferative effects by recruiting and sequestering the adapter protein NUMB at endosomes, thereby impairing trafficking of multiple growth factor receptors. VISTA-expressing tumors exhibit marked sensitivity to VISTA-blocking antibodies, a response that depends on the presence of the NPGF motif. Together, these findings redefine VISTA as a cell-intrinsic regulator of tumor growth and introduce new potential therapeutic avenues that extend beyond receptor-ligand disruption to interfere with checkpoint-mediated intracellular trafficking and signaling. See related article by Zhao et al., p. 3399.